TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficiency of Autologous Platelet Gel (Platelet Rich Fibrin) Obtained From Own Patients' Blood Versus Vaselitulle in Dupuytren's Disease Postoperative Wound Healing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18~* Patient with Dupuytren's disease with an indication of surgical treatment using the open palm technique.~* Agreement form signed~* patient affiliated to the national health system.~Exclusion Criteria:~* Patients allergic to one of the components of the dressings used in this study.~* Patients with insulin-requiring diabetes~* Patients sustaining anti-cancer treatment.~* Pregnant women.~* Patients included in another study.~* Patients who cannot come to the follow up visits.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaselitulle (Type: ACTIVE_COMPARATOR): after surgery, the loss of substance is treated using vaseline dressing
- Autologous platelets gel (Type: EXPERIMENTAL): after surgery, the loss of substance is treated with Autologous platelets gel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Subjects need to fulfill all of the following 4 criteria:~1. Evidence of portal hypertension (by hemodynamic measurement, or by Doppler flow of portal circulation, or by clinical evidence of portal hypertension such as esophageal or gastric varices, as evidenced by prior upper endoscopy).~2. Evidence of pulmonary arterial hypertension by right heart catheterization (all three criteria need to be present) Right heart catheterization may have been performed up to 30 days prior to screening~   * Mean PAP (pulmonary artery pressure) \>25 mm Hg, and~  * PVR (pulmonary vascular resistance) \>240 dynes/s/cm5, and~  * TPG (transpulmonary gradient = meanPAP -PAWP) \>12 mm Hg~3. Baseline AST, ALT \< 5 times the upper limit of normal, total Bili \< 3.0 mg/dl, and mild liver impairment with Child -Pugh class A or B~4. Ages 18 years and above~Exclusion Criteria:~1. Presence of any other etiology of pulmonary arterial hypertension (HIV, connective tissue disease, sickle cell, left heart failure, chronic thromboembolic PH, etc)~2. Treatment with prostacyclins, other ERAs, or PDE5 inhibitors within 30 days of enrollment.~3. Moribund state or anticipated death within 1 month.~4. AST or ALT ≥ 5 times upper limit of normal~5. Total bilirubin ≥ 3.0 mg/dl~6. Significant lung disease (obstructive lung disease with FEV1 \< 1L, or FEV1/FVC \<50%; or restrictive lung disease with Total Lung Capacity \< 60% predicted). PFTs may have been performed up to 6 months prior to enrollment.~7. Pregnancy~8. Age \<18 years~9. Child -Pugh class C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ambrisentan (24 Weeks), Extension (4 Weeks) (Type: OTHER): Open Label Ambrisentan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Proton Therapy for Lymph Nodes in Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed invasive adenocarcinoma of the breast stage I-III (TX, T0-4, N0-3) with medially located tumor and/or axillary node invasion.~* Patients must have undergone either mastectomy or breast conservation surgery.~* Patients are required to have axillary staging which can include sentinel node biopsy alone if sentinel node is negative.~* Patient must require peripheral lymph node radiation per physician discretion.~Exclusion Criteria:~* Evidence of distant metastasis (M1).~* Prior radiotherapy to the area of interest.~* Prior history of cardiovascular disease per physician discretion.~* Prior or concurrent cancer other than non-melanomatous skin cancer unless disease free for at least 5 years.~* Collagen vascular disease, specifically dermatomyositis with a CPK level above normal or with an active skin rash, systemic lupus erythematosis or scleroderma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Conventional photon plan
- 2 (Type: EXPERIMENTAL): 3D-Proton/Conventional plan or 3D-proton only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: P. Knowlesi Trial of Artesunate-mefloquine Versus Chloroquine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients at least 1 year of age and weighing more than 10kg~* Microscopic diagnosis of Plasmodium species infection~* Negative P. falciparum malaria rapid diagnostic test (histidine rich protein 2)~* Fever (temperature 37.5°C) or history of fever in the last 48 hours~* Able to participate in the trial and comply with the clinical trial protocol~* Written informed consent to participate in trial; thumbprint is required for illiterate patients, and written consent from parents/guardian for children below age of consent~Exclusion Criteria:~* Clinical or laboratory criteria for severe malaria, including warning signs, requiring parenteral treatment according to modified WHO criteria (see Appendix 4)~* Parasitaemia \> 20,000 /μL (P. knowlesi)~* Inability to tolerate oral treatment~* Concomitant infection with any other malaria species~* Pregnancy or lactation~* Unable or unwilling to use contraception during study period~* Known hypersensitivity or allergy to artemisinin derivatives~* Serious underlying disease (cardiac, renal or hepatic)~* Received anti-malarials in last 2 months~* Previous psychiatric illness or epilepsy~* Previous episode of cerebral malaria

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Artesunate-mefloquine (Type: ACTIVE_COMPARATOR): 3 doses artesunate-mefloquine - daily over 3 days (dosage according to bodyweight - 4mg/kg and 8.3mg/kg respectively).
- Chloroquine (Type: ACTIVE_COMPARATOR): 4 doses chloroquine over 3 days - total dose 25mg/kg. 10mg/kg at 0 hours, 5mg/kg at 6-8, 24, 48 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of AD113 and Atomoxetine in OSA Patients With Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 25 to 65 years of age, inclusive, at the Screening Visit.~* AHI 10 to 50 (hypopneas defined by 4% oxygen desaturation)~* History of hypertension or blood pressure at Visit 1 ≥130/80 mmHg~Exclusion Criteria:~* History of narcolepsy.~* Clinically significant craniofacial malformation.~* Clinically significant cardiac disease (e.g., rhythm disturbances, coronary artery disease or cardiac failure) or hypertension requiring more than 2 medications for control. A medication for these purposes is defined by dosage form, such that a combination antihypertensive medication is considered 1 medication~* CPAP should not be used for at least 2 weeks prior to first study PSG~* History of using oral or nasal devices for the treatment of OSA may enroll as long as the devices are not used during participation in the study.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AD113 (Type: EXPERIMENTAL): Two oral capsules administered before bed
- Atomoxetine (Type: EXPERIMENTAL): Two oral capsules administered before bed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetic Study of CellCept (Mycophenolate Mofetil) Versus Mycophenolate Sodium in Kidney Transplant Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>/=18 years of age~* kidney transplantation \>/=6 months ago~* on mycophenolic acid-based, calcineurininhibitor-free therapy for \>/=3 months, \>/=1 month on stable dose~* co-therapy with 5mg prednisone for \>/=1 month~Exclusion Criteria:~* active gastrointestinal ulcus~* severe diarrhea od gastrointestinal disease~* severe impairment of renal function~* current malignancy~* Lesch-Nyhan- or Kelley-Seegmiller-Syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MMF, Prednisone (Type: EXPERIMENTAL): Participants received mycophenolate mofetil (MMF) orally (PO) at a dose of 1 gram per day (g/day) twice daily (BID), and prednisone, PO, up to 5 milligrams per day (mg/day) for at least 1 month.
- EC-MPS (Type: ACTIVE_COMPARATOR): Participants received mycophenolate sodium (EC-MPS), PO, at a dose of 720 mg/day BID, and prednisone PO up to 5 mg/day for at least 1 month.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Trazodone & Cognitive Behavioral Therapy to Treat Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic insomnia with duration of more than 1 year~* Objective short sleep duration (\< 6 hours)~* BMI \< 39~* Ages 30-60~* Men \& Women~Exclusion Criteria:~* Major Mental Illness~* Substance Abuse/Dependence~* Sleep Apnea~* Periodic Limb Movement Disorder~* Shift Work or circadian disorders~* Diabetes~* Chronic Renal Failure, Hepatic Insufficiency, Chronic Heart Failure~* Current Use of hypnotics or sleep inducing sedative antidepressants

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Trazodone (Type: ACTIVE_COMPARATOR): None
- Cognitive Behavioral Therapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine Versus Placebo in Chronic Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria: - Male/Female outpatients 18 years of age with chronic low back pain. Exclusion Criteria: - You have a serious or unstable disease of the heart or blood vessels, liver, kidney, lungs, or blood-related illness, problems with decreased blood flow to arms and legs (peripheral vascular disease), or other medical conditions, or psychiatric conditions that, in the opinion of the investigator, would affect your participation or be likely to lead to hospitalization during the course of the study. - Have acute liver injury (such as hepatitis) or severe cirrhosis. - Have had previous exposure to duloxetine. - Have a body mass index (BMI) over 40. - Have major depressive disorder. - Require daily narcotics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Duloxetine 20 mg (Type: EXPERIMENTAL): duloxetine 20 mg once a day (QD), by mouth (PO) for 13 weeks
- Duloxetine 60 mg (Type: EXPERIMENTAL): duloxetine 30 mg once a day (QD), by mouth (PO) for 1 week then duloxetine 60 mg QD, PO for 12 weeks
- Duloxetine 120 mg (Type: EXPERIMENTAL): duloxetine 30 mg once a day (QD), by mouth (PO) for 1 week followed by duloxetine 60 mg QD, PO for 1 week, then duloxetine 120 mg QD, PO for 11 weeks
- Placebo (Type: PLACEBO_COMPARATOR): placebo once a day (QD), by mouth (PO) for 13 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Locally advanced squamous carcinoma of the head and neck (AJCC stages II/IV, M0, and excluding T1N1 and T1N2) undergoing curative intent concurrent chemoradiation.~* Previous treatment of any sort other than a biopsy is not allowed.~* Eligible anatomic sites:~  * oral cavity~ * oropharynx~ * hypopharynx~ * supraglottic~ * glottic larynx~* KPS \> 60~Exclusion Criteria:~* Nasopharynx primary~* History of malignancy other than basal cell skin cancer.~* History of claudication, bleeding, or thromboembolic disorders. Patients receiving heparin or Coumadin therapy are ineligible.~* Primary tumor or lymph node encasement of the carotid artery~* Blood pressure of \>150/100 mmHg~* Unstable angina~* New York Heart Association (NYHA) Grade II or greater congestive heart failure~* History of myocardial infarction within 6 months~* History of stroke within 6 months~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0; anticipation of need for major surgical procedure during the course of the study.~* Minor surgical procedures, fine needle aspirations, or core biopsies within 7 days prior to Day 0~* Pregnant (positive pregnancy test) or lactating~* Urine protein : creatinine ratio ≥ 1.0 at screening~* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0~* Serious, non-healing wound, ulcer, or bone fracture~* AST, ALT, or bilirubin \> 1.5 x normal~* PT or PTT \> 1.5 x normal~* Platelets \< 100,000~* WBC \< 2000~* Hgb \< 10~* Creatinine clearance \< 60 mL/hr~* Refusal to provide written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ChemoRadiotherapy (Type: EXPERIMENTAL): Radiation Therapy concurrent with cisplatin chemotherapy, Avastin and Tarceva

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient or patient's legal guardian must provide written informed consent prior to any protocol-related procedures being performed.~* The patient must have successfully completed Study ALID-003-99 (who received 21 of 26 consecutive weekly infusions).~* The patient has not experienced any safety issues that would contraindicate participation in the Extension study.~* A female patient of childbearing potential must have a negative pregnancy test at entry~Exclusion Criteria:~* The patient is pregnant or lactating.~* The patient has received an investigational drug within 30 days prior to the study enrollment.~* The patient has a medical condition, serious intercurrent illness, or other extenuating circumstance that may significantly interfere with study compliance including all prescribed evaluations and follow-up activities

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo/Aldurazyme (Type: ACTIVE_COMPARATOR): Patients received placebo for 26 weeks in the Double-Blind Study then received 182 weeks of Aldurazyme (0.58 mg/kg every week) in this Extension Study; patients received a total of 182 weeks of Aldurazyme.
- Aldurazyme/Aldurazyme (Type: ACTIVE_COMPARATOR): Patients received 26 weeks of Aldurazyme in the Double-Blind Study and then received 182 weeks of Aldurazyme in this Extension Study; patients received a total of 208 weeks of Aldurazyme.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects between 18 and 65 years of age, with diagnosis of major depressive disorder, as defined by DSM-IV-TR criteria~* The current depressive episode must be equal to or greater than 8 weeks in duration~* Subjects must report a history for the current depressive episode of an inadequate response to no more than three adequate antidepressant treatments~Exclusion Criteria:~* Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug~* Subjects who report an inadequate response to more than three adequate trials of antidepressant treatments during current depressive episode at a therapeutic dose for an adequate duration~* Subjects with a current Axis I (DSM-IV-TR) diagnosis of: Delirium, dementia, amnestic or other cognitive disorder, Schizophrenia, schizoaffective disorder, or other psychotic disorder, Bipolar I or II disorder~* Subjects with a clinically significant current Axis II (DSM-IV-TR) diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Phase B (Type: EXPERIMENTAL): Drug: OPC-34712 + ADT~Drug: Placebo + ADT
- Phase A (Type: PLACEBO_COMPARATOR): Drug: Placebo + ADT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe active disease with presence of at least 4 tender joints and 4 swollen joints.~* Either the patient or a designee must be capable of administering the subcutaneous injection of study drug.~Exclusion Criteria:~* Prior treatment with etanercept.~* Presence of active infection or active or untreated tuberculosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ETN 50mg QW (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* healthy Korean adults (age: over 18 years)~* who got the basic vaccination of DTP(Diphtheria, tetanus, pertussis) in the past~* Subjects willing to provide written informed consent and able to comply with the requirements for the study~Exclusion Criteria:~* subjects who have already got the additional vaccination of Td within 5 years~* subjects with antitoxin of diphtheria and tetanus ≥1.0 IU/mL (ELISA)~  * only applicable in step I~* subjects who have not recovered from the acute disease within 2 weeks~* subjects who have the medical history of allergic disease related to the components of investigational drug~* who got the treatment of blood product and immunoglobulin product within 3 months~* females who are pregnant~* females who are breastfeeding~* subjects who are infected from the diphtheria and tetanus~* subjects who have experienced the severe adverse events for the diphtheria and tetanus vaccination~* Subjects who are scheduled to participate in other clinical trial studies during the study~* Subjects who have participated in any other clinical trials within 4 weeks of the administration of the study~* Those who take the other medicine that affects this study or are vaccinated other vaccines~* Subject who have received adrenocortical hormones or immunosuppressive drug within 4weeks of enrollment~* Subjects with a history of chronic disease obstacles to the study.~* Subjects who have episode of acute febrile (at least 37.4) after injection of vaccine during the study~* Subject who have plan of operation during the study.~* Individuals with other clinically significant medical or psychological condition who are considered by the investigator to be ineligible for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- GC1107 (Type: EXPERIMENTAL): 0.5ml, intramuscular, a single dosing
- Tetanus and Diphtheria(Td vaccine) (Type: ACTIVE_COMPARATOR): 0.5ml, intramuscular, a single dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete